Free tool
Drug Trial Radar: Cardiovascular and metabolic
Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
7
Not yet recruiting, industry sponsors, Cardiovascular and metabolic, Phase 4 (post-approval)
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed906
7 trials
Showing 1 to 7, recently updated first.
- A Clinical Study of MK-7962 in Chinese Participants With Pulmonary Arterial Hypertension (MK-7962-022)Not yet recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07899905 · 40 participants (planned) · Start Nov 30, 2026 · Primary completion Mar 21, 2028
Drug: Sotatercept · For: Hypertension, Pulmonary
- A Phase IV, Two-part, Open-label Study Assessing the Pharmacokinetics, Safety and Pharmacodynamics of Spironolactone Oral Suspension in Pediatric PatientsNot yet recruiting
CMP Development, LLCIndustry
NCT06021860 · 96 participants (planned) · Start Jun 2027 · Primary completion Jun 2028
Drug: Spironolactone Oral Suspension · For: Edema Due to Heart Failure or Cirrhosis
- A Trial Assessing the Effectiveness of Evolocumab in Reducing the Plaque Burden in Participants With Subclinical AtheromaPivotal-lookingNot yet recruiting
AmgenAmgen (AMGN)
NCT07803679 · 308 participants (planned) · Start Jan 31, 2027 · Primary completion Apr 30, 2029
Drug: Evolocumab; Routine Lipid Management · For: Coronary Artery Disease; Hypercholesterolemia; Atheroma and 1 more
- Evaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus PatientsPivotal-lookingNot yet recruiting
Chong Kun Dang PharmaceuticalIndustry
NCT07365358 · 200 participants (planned) · Start Mar 2026 · Primary completion Aug 2027
Drug: empagliflozin 10mg; Glimepiride 1mg · For: Diabete Type 2
Sites: Seoul, South Korea
- Ganagliflozin on the Progression of Kidney Disease in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney DiseasePivotal-lookingNot yet recruiting
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Industry
NCT07116928 · 1,244 participants (planned) · Start Nov 30, 2025 · Primary completion Oct 30, 2031
Drug: ganagliflozin; Placebo · For: T2DM (Type 2 Diabetes Mellitus); CKD - Chronic Kidney Disease
Sites: Shanghai, China
- Clinical Trial to Evaluate the Efficacy and Safety of DA-5218 in Patients With Type 2 DiabetesPivotal-lookingNot yet recruiting
Dong-A ST Co., Ltd.Industry
NCT07229534 · 238 participants (planned) · Start Nov 2025 · Primary completion Nov 2027
Drug: DA-5218; DA-5218-C · For: Diabete Mellitus
- Comparison of the Efficacy and Safety of GLARGEN® Versus NPH Insulin in Diabetic Tunisian Patients.Not yet recruiting
Les Laboratoires des Médicaments StérilesIndustry
NCT06999551 · 60 participants (planned) · Start Jul 1, 2025 · Primary completion Dec 31, 2025
Drug: switch NPH to glargin · For: Diabetes Mellitus
Sites: Sfax, Tunisia
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.